Florence supports more than 200 research sites across the daraxonrasib clinical development program, including 41 sites participating in the pivotal Phase 3 RASolute 302 trial that supported FDA approval.

ATLANTA — August 31, 2026 — Florence Healthcare celebrates a major milestone in the fight against pancreatic cancer following the U.S. Food and Drug Administration’s approval of RASONQUE™ (daraxonrasib), developed by Revolution Medicines, for the treatment of certain adults with metastatic pancreatic adenocarcinoma.

The approval marks the arrival of the first FDA-approved broad RAS-targeted medicine for metastatic pancreatic cancer, a disease that has historically had few effective treatment options and remains one of the most difficult cancers to treat. (fda.gov)

For Florence, the milestone is especially meaningful. More than 200 research sites participating across the daraxonrasib clinical development program are using Florence technology to support their clinical trial operations, including 41 sites in the pivotal Phase 3 RASolute 302 study that formed the basis of the FDA approval.

It is a tangible example of Florence’s mission—to connect research sites and sponsors to accelerate trials and cures—coming to life.

A Significant Advance for Patients With Pancreatic Cancer

Pancreatic cancer has long represented one of oncology’s most difficult challenges. The disease is often diagnosed after it has already spread, leaving patients with limited treatment options and poor survival rates.

RASONQUE changes what is possible for some of these patients.

The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval was based on results from RASolute 302, a randomized, open-label Phase 3 trial involving 500 patients. (fda.gov)

In the study, patients receiving daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months for patients receiving standard-of-care chemotherapy. The treatment reduced the risk of death by 60% and also significantly improved progression-free survival and objective response rates. (fda.gov, ir.revmed.com)

Behind those numbers is what matters most.

More time for patients to spend with their families. More birthdays, holidays and ordinary days together. And for a cancer in which progress has historically been difficult to achieve, a new treatment option and a new source of hope.

Behind Every Breakthrough Are Research Sites

FDA approval may be the moment a new therapy becomes available to patients, but getting there requires years of work across sponsors, investigators, research sites, coordinators, patients and caregivers.

The RASolute 302 trial was a global Phase 3 program evaluating daraxonrasib against standard-of-care chemotherapy in patients with previously treated metastatic pancreatic adenocarcinoma. (ir.revmed.com)

Research sites are responsible for the essential work of bringing that study to patients and executing it safely and consistently, from managing regulatory documentation and study workflows to coordinating with sponsors and maintaining inspection-ready records.

Florence technology is supporting 41 of those RASolute 302 research sites.

Across the broader daraxonrasib clinical development program, Florence continues to support more than 200 participating research sites, helping provide the digital infrastructure those teams relied on to manage the operational work behind the research.

Technology in Service of Research

Clinical trial technology can sometimes feel far removed from the patient.

A document exchanged between a sponsor and site. A regulatory file completed. A study workflow moved forward. A monitor able to review records remotely. An administrative task eliminated from a coordinator’s day.

Individually, these are operational moments. Together, they are part of the infrastructure required to move a potential treatment through clinical research and, ultimately, into the hands of patients.

Florence exists to make that infrastructure work better.

Today, Florence supports more than 80,000 research sites and 600 sponsors and CROs across 90 countries, connecting the organizations developing new therapies with the research teams responsible for bringing clinical trials to patients.

The approval of RASONQUE is a reminder of why that work matters.

When research moves forward, patients gain possibilities they did not have before.

Celebrating the Teams That Made This Possible

Florence congratulates Revolution Medicines and the investigators, clinical research professionals, site teams, patients and families whose participation made the daraxonrasib clinical program possible.

For the research coordinators and site teams in particular, breakthroughs like this are built through thousands of often-unseen moments.

Florence is proud to be supporting more than 200 of those sites along the way.

This is what it means to drive research and accelerate cures.

Read the FDA approval announcement

About Florence Healthcare

Florence Healthcare is the leading provider of clinical trial site software, supporting more than 80,000 research sites and 600 sponsors and CROs across 90 countries. The Florence Trial Operations Platform connects sponsors and research sites to streamline study startup, document exchange, remote monitoring and other critical clinical trial workflows.

Want to simplify and scale your studies? Learn more